Chromatin conformation capture in the clinic: 4C-seq/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus.

4C Chromosome microarray Enhancer GPR101 HiC Neo-TAD Pituitary tumor Prenatal diagnosis Topologically associating domains X-linked acrogigantism

Journal

Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844

Informations de publication

Date de publication:
13 Sep 2024
Historique:
received: 16 05 2024
accepted: 23 08 2024
medline: 14 9 2024
pubmed: 14 9 2024
entrez: 13 9 2024
Statut: epublish

Résumé

X-linked acrogigantism (X-LAG; MIM: 300942) is a severe form of pituitary gigantism caused by chromosome Xq26.3 duplications involving GPR101. X-LAG-associated duplications disrupt the integrity of the topologically associating domain (TAD) containing GPR101 and lead to the formation of a neo-TAD that drives pituitary GPR101 misexpression and gigantism. As X-LAG is fully penetrant and heritable, duplications involving GPR101 identified on prenatal screening studies, like amniocentesis, can pose an interpretation challenge for medical geneticists and raise important concerns for patients and families. Therefore, providing robust information on the functional genomic impact of such duplications has important research and clinical value with respect to gene regulation and triplosensitivity traits. We employed 4C/HiC-seq as a clinical tool to determine the functional impact of incidentally discovered GPR101 duplications on TAD integrity in three families. After defining duplications and breakpoints around GPR101 by clinical-grade and high-density aCGH, we constructed 4C/HiC chromatin contact maps for our study population and compared them with normal and active (X-LAG) controls. We showed that duplications involving GPR101 that preserved the centromeric invariant TAD boundary did not generate a pathogenic neo-TAD and that ectopic enhancers were not adopted. This allowed us to discount presumptive/suspected X-LAG diagnoses and GPR101 misexpression, obviating the need for intensive clinical follow-up. This study highlights the importance of TAD boundaries and chromatin interactions in determining the functional impact of copy number variants and provides proof-of-concept for using 4C/HiC-seq as a clinical tool to acquire crucial information for genetic counseling and to support clinical decision-making in cases of suspected TADopathies.

Sections du résumé

BACKGROUND BACKGROUND
X-linked acrogigantism (X-LAG; MIM: 300942) is a severe form of pituitary gigantism caused by chromosome Xq26.3 duplications involving GPR101. X-LAG-associated duplications disrupt the integrity of the topologically associating domain (TAD) containing GPR101 and lead to the formation of a neo-TAD that drives pituitary GPR101 misexpression and gigantism. As X-LAG is fully penetrant and heritable, duplications involving GPR101 identified on prenatal screening studies, like amniocentesis, can pose an interpretation challenge for medical geneticists and raise important concerns for patients and families. Therefore, providing robust information on the functional genomic impact of such duplications has important research and clinical value with respect to gene regulation and triplosensitivity traits.
METHODS METHODS
We employed 4C/HiC-seq as a clinical tool to determine the functional impact of incidentally discovered GPR101 duplications on TAD integrity in three families. After defining duplications and breakpoints around GPR101 by clinical-grade and high-density aCGH, we constructed 4C/HiC chromatin contact maps for our study population and compared them with normal and active (X-LAG) controls.
RESULTS RESULTS
We showed that duplications involving GPR101 that preserved the centromeric invariant TAD boundary did not generate a pathogenic neo-TAD and that ectopic enhancers were not adopted. This allowed us to discount presumptive/suspected X-LAG diagnoses and GPR101 misexpression, obviating the need for intensive clinical follow-up.
CONCLUSIONS CONCLUSIONS
This study highlights the importance of TAD boundaries and chromatin interactions in determining the functional impact of copy number variants and provides proof-of-concept for using 4C/HiC-seq as a clinical tool to acquire crucial information for genetic counseling and to support clinical decision-making in cases of suspected TADopathies.

Identifiants

pubmed: 39272130
doi: 10.1186/s13073-024-01378-5
pii: 10.1186/s13073-024-01378-5
doi:

Substances chimiques

Receptors, G-Protein-Coupled 0
Chromatin 0
GPR101 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112

Subventions

Organisme : Fondazione Telethon
ID : GGP20130
Organisme : Centre Hospitalier Universitaire de Liège
ID : 2018/20
Organisme : Eunice Kennedy Shriver National Institute of Child Health and Human Development
ID : Z1A HD008920
Organisme : National Institute of Health (NINDS)
ID : R35NS105078
Organisme : Ministero della Salute
ID : Ricerca Corrente"
Organisme : Ministero della Salute
ID : T3-AN-14 "LifeMap"
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : PRIN PNRR 2022
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : PRIN 2022
Organisme : 'la Caixa' Foundation
ID : 100010434
Organisme : 'la Caixa' Foundation
ID : fellowship code LCF/BQ/PR22/11920006

Informations de copyright

© 2024. The Author(s).

Références

Ibrahim DM, Mundlos S. Three-dimensional chromatin in disease: what holds us together and what drives us apart? Curr Opin Cell Biol. 2020;64:1–9. https://doi.org/10.1016/j.ceb.2020.01.003 .
doi: 10.1016/j.ceb.2020.01.003 pubmed: 32036200
da Costa-Nunes JA, Noordermeer D. TADs: dynamic structures to create stable regulatory functions. Curr Opin Struct Biol. 2023;81:102622. https://doi.org/10.1016/j.sbi.2023.102622 .
doi: 10.1016/j.sbi.2023.102622 pubmed: 37302180
Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature. 2012;485:376–80. https://doi.org/10.1038/nature11082 .
doi: 10.1038/nature11082 pubmed: 22495300 pmcid: 3356448
Phillips-Cremins JE, Sauria MEG, Sanyal A, Gerasimova TI, Lajoie BR, Bell JSK, et al. Architectural protein subclasses shape 3D organization of genomes during lineage commitment. Cell. 2013;153:1281–95. https://doi.org/10.1016/J.CELL.2013.04.053 .
doi: 10.1016/J.CELL.2013.04.053 pubmed: 23706625 pmcid: 3712340
Lupiáñez DG, Spielmann M, Mundlos S. Breaking TADs: how alterations of chromatin domains result in disease. Trends Genet. 2016;32:225–37. https://doi.org/10.1016/J.TIG.2016.01.003 .
doi: 10.1016/J.TIG.2016.01.003 pubmed: 26862051
Rajderkar S, Barozzi I, Zhu Y, Hu R, Zhang Y, Li B, et al. Topologically associating domain boundaries are required for normal genome function. Commun Biol. 2023;6:435. https://doi.org/10.1038/s42003-023-04819-w .
doi: 10.1038/s42003-023-04819-w pubmed: 37081156 pmcid: 10119121
Franke M, Ibrahim DM, Andrey G, Schwarzer W, Heinrich V, Schöpflin R, et al. Formation of new chromatin domains determines pathogenicity of genomic duplications. Nature. 2016;538:265–9. https://doi.org/10.1038/nature19800 .
doi: 10.1038/nature19800 pubmed: 27706140
Lupiáñez DG, Kraft K, Heinrich V, Krawitz P, Brancati F, Klopocki E, et al. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. Cell. 2015;161:1012–25. https://doi.org/10.1016/j.cell.2015.04.004 .
doi: 10.1016/j.cell.2015.04.004 pubmed: 25959774 pmcid: 4791538
Matharu N, Ahituv N. Minor loops in major folds: enhancer-promoter looping, chromatin restructuring, and their association with transcriptional regulation and disease. PLoS Genet. 2015;11:e1005640. https://doi.org/10.1371/journal.pgen.1005640 .
doi: 10.1371/journal.pgen.1005640 pubmed: 26632825 pmcid: 4669122
Xu Z, Lee DS, Chandran S, Le VT, Bump R, Yasis J, et al. Structural variants drive context dependent oncogene activation in cancer. Nature. 2022;612:564. https://doi.org/10.1038/S41586-022-05504-4 .
doi: 10.1038/S41586-022-05504-4 pubmed: 36477537 pmcid: 9810360
de Bruijn SE, Fiorentino A, Ottaviani D, Fanucchi S, Melo US, Corral-Serrano JC, et al. Structural variants create new topological-associated domains and ectopic retinal enhancer-gene contact in dominant retinitis pigmentosa. Am J Hum Genet. 2020;107:802–14. https://doi.org/10.1016/j.ajhg.2020.09.002 .
doi: 10.1016/j.ajhg.2020.09.002 pubmed: 33022222 pmcid: 7675008
Kim K, Kim M, Lee AJ, Song SH, Kang JK, Eom J, et al. Spatial and clonality-resolved 3D cancer genome alterations reveal enhancer-hijacking as a potential prognostic marker for colorectal cancer. Cell Rep 2023;42. https://doi.org/10.1016/J.CELREP.2023.112778 .
Pagnamenta AT, Yu J, Walker S, Noble AJ, Lord J, Dutta P, et al. The impact of inversions across 33,924 families with rare disease from a national genome sequencing project. Am J Hum Genet. 2024;111:1140–64. https://doi.org/10.1016/J.AJHG.2024.04.018 .
doi: 10.1016/J.AJHG.2024.04.018 pubmed: 38776926 pmcid: 11179413
Andrey G, Duboule D. Genetic cold cases: lessons from solving complex congenital limb disorders. Genes Dev. 2023;37:261–76. https://doi.org/10.1101/GAD.350450.123 .
doi: 10.1101/GAD.350450.123 pubmed: 36990510 pmcid: 10153463
Cova G, Glaser J, Schöpflin R, Prada-Medina CA, Ali S, Franke M, et al. Combinatorial effects on gene expression at the Lbx1/Fgf8 locus resolve split-hand/foot malformation type 3. Nat Commun. 2023;14:1475. https://doi.org/10.1038/s41467-023-37057-z .
Franke M, Daly AF, Palmeira L, Tirosh A, Stigliano A, Trifan E, et al. Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism. Am J Hum Genet. 2022;109:553–70. https://doi.org/10.1016/j.ajhg.2022.02.002 .
Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371:2363–74. https://doi.org/10.1056/NEJMoa1408028 .
Abboud D, Daly AF, Dupuis N, Bahri MA, Inoue A, Chevigné A, et al. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11. Nat Commun. 2020;11:4752. https://doi.org/10.1038/s41467-020-18500-x .
doi: 10.1038/s41467-020-18500-x pubmed: 32958754 pmcid: 7506554
Costanzi S, Stahr LG, Trivellin G, Stratakis CA. GPR101: modeling a constitutively active receptor linked to X-linked acrogigantism. J Mol Graph Model 2023;127. https://doi.org/10.1016/J.JMGM.2023.108676 .
Abboud D, Abboud C, Inoue A, Twizere J-C, Hanson J. Basal interaction of the orphan receptor GPR101 with arrestins leads to constitutive internalization. Biochem Pharmacol. 2024;220:116013. https://doi.org/10.1016/j.bcp.2023.116013 .
doi: 10.1016/j.bcp.2023.116013 pubmed: 38151077
Yang Z, Wang J-Y, Yang F, Zhu K-K, Wang G-P, Guan Y, et al. Structure of GPR101-Gs enables identification of ligands with rejuvenating potential. Nat Chem Biol 2023. https://doi.org/10.1038/s41589-023-01456-6
Trivellin G, Tirosh A, Hernández-Ramírez LC, Gupta T, Tsai-Morris CH, Faucz FR, et al. The X-linked acrogigantism-associated gene gpr101 is a regulator of early embryonic development and growth in zebrafish. Mol Cell Endocrinol. 2021;520:111091. https://doi.org/10.1016/j.mce.2020.111091 .
Daly AF, Yuan B, Fina F, Caberg J-H, Trivellin G, Rostomyan L, et al. Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. Endocr Relat Cancer. 2016;23:221–33. https://doi.org/10.1530/ERC-16-0082 .
doi: 10.1530/ERC-16-0082 pubmed: 26935837 pmcid: 4877443
Beckers A, Lodish MB, Trivellin G, Rostomyan L, Lee M, Faucz FR, et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer. 2015;22:353–67. https://doi.org/10.1530/ERC-15-0038 .
doi: 10.1530/ERC-15-0038 pubmed: 25712922 pmcid: 4433400
Iacovazzo D, Caswell R, Bunce B, Jose S, Yuan B, Hernández-Ramírez LC, et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol Commun. 2016;4:56. https://doi.org/10.1186/s40478-016-0328-1 .
Wise-Oringer BK, Zanazzi GJ, Gordon RJ, Wardlaw SL, William C, Anyane-Yeboa K, et al. Familial X-linked acrogigantism: postnatal outcomes and tumor pathology in a prenatally diagnosed infant and his mother. J Clin Endocrinol Metab. 2019;104:4667–75. https://doi.org/10.1210/jc.2019-00817 .
doi: 10.1210/jc.2019-00817 pubmed: 31166600 pmcid: 6736216
Naves LA, Daly AF, Dias LA, Yuan B, Zakir JCO, Barra GB, et al. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. Endocrine. 2016;51:236–44. https://doi.org/10.1007/s12020-015-0804-6 .
doi: 10.1007/s12020-015-0804-6 pubmed: 26607152
Grob S, Cavalli G. Technical review: a hitchhiker’s guide to chromosome conformation capture. Methods Mol Biol. 2018;1675:233–46. https://doi.org/10.1007/978-1-4939-7318-7_14 .
doi: 10.1007/978-1-4939-7318-7_14 pubmed: 29052195
Trivellin G. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE193114 2023.
Trivellin G. 4C-seq/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus: clinical application of chromatin conformation capture techniques to refine genetic diagnosis 2024. https://doi.org/10.5281/zenodo.11106834 .
Noordermeer D, Leleu M, Schorderet P, Joye E, Chabaud F, Duboule D. Temporal dynamics and developmental memory of 3D chromatin architecture at Hox gene loci. Elife. 2014;3:e02557. https://doi.org/10.7554/eLife.02557 .
Wickham H. ggplot2. Cham: Springer International Publishing; 2016. https://doi.org/10.1007/978-3-319-24277-4 .
Rao SSP, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell. 2014;159:1665–80. https://doi.org/10.1016/J.CELL.2014.11.021 .
doi: 10.1016/J.CELL.2014.11.021 pubmed: 25497547 pmcid: 5635824
Franke M, De la Calle-Mustienes E, Neto A, Almuedo-Castillo M, Irastorza-Azcarate I, Acemel RD, et al. CTCF knockout in zebrafish induces alterations in regulatory landscapes and developmental gene expression. Nat Commun. 2021;12:5415. https://doi.org/10.1038/s41467-021-25604-5 .
doi: 10.1038/s41467-021-25604-5 pubmed: 34518536 pmcid: 8438036
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–60. https://doi.org/10.1093/bioinformatics/btp324 .
doi: 10.1093/bioinformatics/btp324 pubmed: 19451168 pmcid: 2705234
Durand NC, Shamim MS, Machol I, Rao SSP, Huntley MH, Lander ES, et al. Juicer provides a one-click system for analyzing loop-resolution Hi-C experiments. Cell Syst. 2016;3:95–8. https://doi.org/10.1016/J.CELS.2016.07.002 .
doi: 10.1016/J.CELS.2016.07.002 pubmed: 27467249 pmcid: 5846465
Kruse K, Hug CB, Vaquerizas JM. FAN-C: a feature-rich framework for the analysis and visualisation of chromosome conformation capture data. Genome Biol. 2020;21:303. https://doi.org/10.1186/s13059-020-02215-9 .
doi: 10.1186/s13059-020-02215-9 pubmed: 33334380 pmcid: 7745377
Trivellin G, Faucz FR, Daly AF, Beckers A, Stratakis CA. Hereditary endocrine tumours: current state-of-the-art and research opportunities: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis. Endocr Relat Cancer. 2020;27:T87-97. https://doi.org/10.1530/ERC-20-0025 .
doi: 10.1530/ERC-20-0025 pubmed: 32240984
Daly AF, Beckers A. The genetic pathophysiology and clinical management of the TADopathy, X-linked acrogigantism. Endocr Rev 2024:bnae014. https://doi.org/10.1210/endrev/bnae014 .
Xu Z, Lee DS, Chandran S, Le VT, Bump R, Yasis J, et al. Structural variants drive context-dependent oncogene activation in cancer. Nature. 2022;612(7940):564–72. https://doi.org/10.1038/s41586-022-05504-4 .
doi: 10.1038/s41586-022-05504-4 pubmed: 36477537 pmcid: 9810360
Sánchez-Gaya V, Rada-Iglesias A. POSTRE: a tool to predict the pathological effects of human structural variants. Nucleic Acids Res. 2023;51:e54–e54. https://doi.org/10.1093/NAR/GKAD225 .
doi: 10.1093/NAR/GKAD225 pubmed: 36999617 pmcid: 10201441
Monaghan KG, Leach NT, Pekarek D, Prasad P, Rose NC. The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22:675–80. https://doi.org/10.1038/s41436-019-0731-7 .
doi: 10.1038/s41436-019-0731-7 pubmed: 31911674
Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YM, Monaghan KG, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25:100336. https://doi.org/10.1016/j.gim.2022.11.004 .
doi: 10.1016/j.gim.2022.11.004 pubmed: 36524989
Hillman SC, McMULLAN DJ, Hall G, Togneri FS, James N, Maher EJ, et al. Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta-analysis 2013.  https://doi.org/10.1002/uog.12464
Basel-Salmon L, Sukenik-Halevy R. Challenges in variant interpretation in prenatal exome sequencing. Eur J Med Genet. 2022;65:104410. https://doi.org/10.1016/J.EJMG.2021.104410 .
doi: 10.1016/J.EJMG.2021.104410 pubmed: 34952236
Muys J, Blaumeiser B, Janssens K, Loobuyck P, Jacquemyn Y. Chromosomal microarray analysis in prenatal diagnosis: ethical considerations of the Belgian approach. J Med Ethics. 2020;46:104–9. https://doi.org/10.1136/MEDETHICS-2018-105186 .
doi: 10.1136/MEDETHICS-2018-105186 pubmed: 31527144
Chakravorty S, Hegde M. Inferring the effect of genomic variation in the new era of genomics. Hum Mutat. 2018;39:756–73. https://doi.org/10.1002/HUMU.23427 .
doi: 10.1002/HUMU.23427 pubmed: 29633501

Auteurs

Adrian F Daly (AF)

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.

Leslie A Dunnington (LA)

Department of Pediatrics, Division of Medical Genetics, McGovern Medical School, University of Texas Health Science Center (UTHealth Houston), Houston, TX, USA.
Memorial Hermann-Texas Medical Center, University of Texas Health Science Center at Houston, Houston, TX, USA.

David F Rodriguez-Buritica (DF)

Department of Pediatrics, Division of Medical Genetics, McGovern Medical School, University of Texas Health Science Center (UTHealth Houston), Houston, TX, USA.
Memorial Hermann-Texas Medical Center, University of Texas Health Science Center at Houston, Houston, TX, USA.

Erica Spiegel (E)

Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, 10032, USA.

Francesco Brancati (F)

Department of Life, Health and Environmental Sciences, University of L'Aquila, Via Spennati N.1, L'Aquila, 67010, Italy.
Human Functional Genetics Laboratory, IRCCS San Raffaele Roma, Rome, Italy.

Giovanna Mantovani (G)

Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Vandana M Rawal (VM)

Austin Diagnostic Clinic, 2400 Cedar Bend Dr, Austin, TX, 78758, USA.

Fabio Rueda Faucz (FR)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, MD, USA.

Hadia Hijazi (H)

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.

Jean-Hubert Caberg (JH)

Department of Human Genetics, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.

Anna Maria Nardone (AM)

Medical Genetics Laboratory, Policlinico Tor Vergata Hospital, Viale Oxford 81, Rome, 00133, Italy.

Mario Bengala (M)

Medical Genetics Laboratory, Policlinico Tor Vergata Hospital, Viale Oxford 81, Rome, 00133, Italy.

Paola Fortugno (P)

Human Functional Genetics Laboratory, IRCCS San Raffaele Roma, Rome, Italy.
Università Telematica San Raffaele, Rome, Italy.

Giulia Del Sindaco (G)

Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Marta Ragonese (M)

Department of Human Pathology of Adulthood and Childhood DETEV, Endocrinology Unit, University of Messina, 98125, Messina, Italy.

Helen Gould (H)

Austin Maternal Fetal Medicine, 12200 Renfert Way Ste G3, Austin, TX, 78758, USA.

Salvatore Cannavò (S)

Department of Human Pathology of Adulthood and Childhood DETEV, Endocrinology Unit, University of Messina, 98125, Messina, Italy.

Patrick Pétrossians (P)

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.

Andrea Lania (A)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, 20072, Italy.
IRCCS Humanitas Research Hospital, Milan, Italy.

James R Lupski (JR)

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
Texas Children's Hospital, Houston, TX, USA.

Albert Beckers (A)

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.

Constantine A Stratakis (CA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, MD, USA.
Human Genetics and Precision Medicine, Institute of Molecular Biology and Biotechnology (IMBB), Foundation for Research and Technology Hellas, Heraklion, Greece.
ASTREA Health, Athens, Greece.

Brynn Levy (B)

Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.

Giampaolo Trivellin (G)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, 20072, Italy. giampaolo.trivellin@hunimed.eu.
IRCCS Humanitas Research Hospital, Milan, Italy. giampaolo.trivellin@hunimed.eu.

Martin Franke (M)

Andalusian Center for Developmental Biology (CABD), Junta de Andalucia - Universidad Pablo de Olavide (UPO) - Consejo Superior de Investigaciones Cientificas (CSIC), Seville, Spain. mfra2@upo.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH